Want to see TSE:ATLE full AI Analyst Report?

Willow Biosciences Inc (ATLE) Price & Analysis

36 Followers

ATLE Stock Chart & Stats

C$0.18

Market closed

C$0.18

Day’s Range― - ―

52-Week RangeC$0.12 - C$0.30

Previous CloseN/A

VolumeN/A

Average Volume (3M)26.24K

Market Cap

C$47.55M

Enterprise Value-C$8.51M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding352,222,660

10 Day Avg. Volume47,704

30 Day Avg. Volume26,236

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue GrowthA nearly 300% revenue increase signifies accelerating product adoption and expanding customer traction for Willow's fermentation-derived ingredients. This durable top-line momentum supports scale effects, improves leverage on fixed costs, and strengthens the case for continued commercial expansion over the next several months.

Defensible Precision Fermentation ModelWillow's core capability in microbial strain engineering, fermentation and downstream processing is a structural competitive advantage. Precision fermentation addresses sustainability and purity trends in consumer goods, enabling long-term demand, potential premium pricing, and partnership opportunities with CPG and industrial customers.

Improving Free Cash FlowA substantial reduction in free cash outflow reflects better cost control and operational progress. This durable improvement lengthens runway, reduces near-term financing pressure, and provides management more flexibility to prioritize commercialization and margin expansion over the coming months if the trend continues.

Bears Say

Negative Shareholders' EquityNegative equity indicates solvency strain and weak balance sheet resilience. This structural weakness limits borrowing capacity, raises creditor and investor concerns, and increases the likelihood of dilutive financing or onerous terms—factors that materially affect strategic flexibility for months ahead.

Ongoing Negative Operating Cash FlowPersistent negative operating cash flow shows the business is not yet self-sustaining and remains reliant on external capital. Continued cash burn constrains investment in scale-up and commercialization, heightens refinancing risk, and can force short-term tradeoffs that impair long-term execution.

Sustained Net LossesDespite revenue growth and gross margin improvement, net losses and negative EBIT margins persist, driven by operating expenses. This structural profitability gap must be closed to achieve durable cash generation; until then, profitability remains a multi-quarter risk to financial stability and scaling plans.

Willow Biosciences Inc News

Atlas Energy Highlights Strong Cash Position and Growing Deal Pipeline for 2025

Willow Biosciences Inc ( ($TSE:ATLE) ) just unveiled an announcement. Atlas Energy Corp., an international upstream royalty and...

3M ago

Atlas Energy Corp. Expands Deal Pipeline Amid Favorable Market Conditions

Willow Biosciences Inc ( ($TSE:ATLE) ) just unveiled an update. Atlas Energy Corp. has released its unaudited consolidated...

8M ago

Atlas Energy Reports Strong Q2 2025 Results and Strategic Recapitalization

Willow Biosciences Inc ( ($TSE:ATLE) ) has shared an announcement. Atlas Energy Corp. has announced its second-quarter financial...

10M ago

Atlas Energy Corp. Appoints Andy Duncan to Bolster Leadership Team

Willow Biosciences Inc ( ($TSE:ATLE) ) just unveiled an announcement. Atlas Energy Corp. has appointed Andy Duncan as...

11M ago

ATLE FAQ

What was Willow Biosciences Inc’s price range in the past 12 months?

Willow Biosciences Inc lowest stock price was C$0.12 and its highest was C$0.30 in the past 12 months.

What is Willow Biosciences Inc’s market cap?

Willow Biosciences Inc’s market cap is C$47.55M.

When is Willow Biosciences Inc’s upcoming earnings report date?

Willow Biosciences Inc’s upcoming earnings report date is Aug 11, 2026 which is in 40 days.

How were Willow Biosciences Inc’s earnings last quarter?

Currently, no data Available

Is Willow Biosciences Inc overvalued?

According to Wall Street analysts Willow Biosciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Willow Biosciences Inc pay dividends?

Willow Biosciences Inc does not currently pay dividends.

What is Willow Biosciences Inc’s EPS estimate?

Willow Biosciences Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Willow Biosciences Inc have?

Willow Biosciences Inc has 352,222,660 shares outstanding.

What happened to Willow Biosciences Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Willow Biosciences Inc?

Currently, no hedge funds are holding shares in TSE:ATLE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Willow Biosciences Inc

Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.